Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 in Idiopathic Pulmonary Fibrosis (Phase III)
CTR20223283Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nerandomilast in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Dec 2022; status: completed.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20223283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223283.